Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Bullboard Posts
Comment by mercedesmanon May 21, 2020 10:06am
213 Views
Post# 31055715

RE:Just got the AGM paperworks

RE:Just got the AGM paperworks
GoldenInvestor0 wrote:

Just got the agm paperworks. 

What are the drawbacks if we are in for a 1 to 10 or 1 to 20 reverse split ?



No drawbacks - if it gets us on the Nasdaq.  In fact it would be a necessary first step to doing so.

Critics of RS's will say that stocks typically fall after a reverse split.   That would be true if the Company DOESN'T have the goods (and it's merely an attempt to uplist, with only hype behind it - ie. no fundamentals, limited to no future cash flow prospects)

Companies that HAVE the goods (Spectral) will benefit through (1) meeting minimum share price thresholds, (2)  institutional exposure that requires investable stocks to have prices over say $ 1 or $ 5, and (3) vastly increased exposure to key markets (e.g US)

My preference would be a lower RS ratio (e.g 10:1).  Would have preferred 5:1 to be an option (or even 8:1).   If for example FDA approval of DIMI pushed the stock to over $ 1 CAD, a 5:1 or more would be fine. But that would require at least a minimal marketing effort as well.

Example $ 1.20 CAD x 8 = $9.60 CAD = $ 6.85 USD   (well above the $ 3 or $ 5 Nasdaq thresholds)

MM




Bullboard Posts